MX2021011688A - Combinaciones utiles en un metodo para tratar sarcoma. - Google Patents

Combinaciones utiles en un metodo para tratar sarcoma.

Info

Publication number
MX2021011688A
MX2021011688A MX2021011688A MX2021011688A MX2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A
Authority
MX
Mexico
Prior art keywords
treating sarcoma
subject
useful combinations
sarcoma
treating
Prior art date
Application number
MX2021011688A
Other languages
English (en)
Spanish (es)
Inventor
Marla L Weetall
Liangxian Cao
Josephine Sheedy
Robert Spiegel
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2021011688A publication Critical patent/MX2021011688A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021011688A 2019-03-27 2020-03-27 Combinaciones utiles en un metodo para tratar sarcoma. MX2021011688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825017P 2019-03-27 2019-03-27
PCT/US2020/025532 WO2020198705A1 (en) 2019-03-27 2020-03-27 Combinations useful in a method for treating sarcoma

Publications (1)

Publication Number Publication Date
MX2021011688A true MX2021011688A (es) 2022-01-24

Family

ID=72609016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011688A MX2021011688A (es) 2019-03-27 2020-03-27 Combinaciones utiles en un metodo para tratar sarcoma.

Country Status (11)

Country Link
US (1) US20220152024A1 (https=)
EP (1) EP3947379A4 (https=)
JP (1) JP7602481B2 (https=)
CN (1) CN114096537B (https=)
AU (1) AU2020248103A1 (https=)
BR (1) BR112021019170A2 (https=)
CA (1) CA3134648A1 (https=)
EA (1) EA202192349A1 (https=)
IL (1) IL286647A (https=)
MX (1) MX2021011688A (https=)
WO (1) WO2020198705A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (https=) * 1973-09-20 1977-11-30 Delalande Sa
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2007335744A1 (en) * 2006-12-20 2008-06-26 Alberto A. Gabizon Method for administration of pegylated liposomal doxorubicin
KR20220143164A (ko) * 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 bmi-1 저해제
CN113164479A (zh) * 2018-08-17 2021-07-23 Ptc医疗公司 用于治疗胰腺癌的方法
SG11202109503TA (en) * 2019-03-11 2021-09-29 Ptc Therapeutics Inc Compound form having enhanced bioavailability and formulations thereof

Also Published As

Publication number Publication date
EP3947379A1 (en) 2022-02-09
JP7602481B2 (ja) 2024-12-18
CN114096537B (zh) 2025-01-10
EA202192349A1 (ru) 2022-02-01
CA3134648A1 (en) 2020-10-01
US20220152024A1 (en) 2022-05-19
CN114096537A (zh) 2022-02-25
WO2020198705A1 (en) 2020-10-01
AU2020248103A1 (en) 2021-10-21
IL286647A (en) 2021-10-31
JP2022519930A (ja) 2022-03-25
EP3947379A4 (en) 2022-12-21
BR112021019170A2 (pt) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
CL2017000507A1 (es) Derivados de benzodiazepina citotóxicos
CL2025002456A1 (es) Agonistas heterocíclicos de glp-1
CL2020003276A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
CL2019002797A1 (es) Preservantes para madera.
MX389499B (es) Metodos, composiciones y usos relacionados con los mismos
MX389692B (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc.
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2019003545A (es) Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas.
CO2021000087A2 (es) Combinación de factor vii y de un anticuerpo biespecífico dirigido contra los factores ix y x
GB2543709A (en) Pharmaceutical agent
MX2016002308A (es) Tratamiento del mieloma multiple.
MX2021011688A (es) Combinaciones utiles en un metodo para tratar sarcoma.
MX2016002307A (es) Tratamiento para el cancer.
WO2020180842A3 (en) Aptamers and use thereof
PE20200749A1 (es) Moduladores de la expresion de enac
EA202091694A1 (ru) Ингибиторы pd-1/pd-l1
EA201990443A1 (ru) Новое применение n,n-бис-2 -меркаптоэтилизофталамида